PCM
SYRE icon

Prelude Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Prelude Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-16
Closed -$3K – 1961
2020
Q3 		$3K Buy
+16
New +$2.96K ﹤0.01% 1640
2017
Q3 		– Sell
-5
Closed – – 1890
2017
Q2 		$0 Buy
+5
New +$691 ﹤0.01% 1841

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Prelude Capital Management's SYRE Position: Q4 2020 in Review

Prelude Capital Management sold out of Spyre Therapeutics (SYRE) in Q4 2020, closing a stake of 16 shares — an estimated $3K sold.

Prelude Capital Management first reported a position in SYRE in Q2 2017 and held it in 2 quarters. The position peaked at $3K in Q3 2020. 92 funds tracked by Wall St. Rank hold SYRE as of Q4 2020.

  • Prelude Capital Management reported no remaining Spyre Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 16 Spyre Therapeutics shares in Q4 2020, an estimated $3K.
  • Prelude Capital Management first reported a position in Spyre Therapeutics in Q2 2017 and held it in 2 quarters.
  • Prelude Capital Management's Spyre Therapeutics position peaked at $3K in Q3 2020.
  • 92 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.